Skip to main content

Table 1 Base-line characteristics of the 475 subjects and results of serum testing

From: Diagnostic value of immunoglobulin G antibodies against Candida enolase and fructose-bisphosphate aldolase for candidemia

  Number [anti-Eno (%) positive; anti-Fba1(%) positive]
   Control group
Characteristic Patients with candidemia Patients with candida colonization Patients with bacteremia Patients with IAa Healthy subjects
  n = 101 n = 50 n = 84 n = 40 n = 200
Demographic factors      
 Sex      
  Male 63 (73.0, 82.5)f 41 (7.3; 7.3) 52 (3.8,19.2) 33 (6.1; 0) 117 (2.6; 5.1)
  Female 38 (71.1, 94.7) 9 (22.2; 22.2) 32 (6.3; 9.4) 7 (14.3; 14.3) 83 (1.2; 2.4)
 Age (years, mean ± SD) 52.3 ± 19.6 76.12 ± 14.89 51.9 ± 14.2 57.6 ± 15.8 59.1 ± 12.4
  ≤65 years 71 (69.0, 87.3)g 9 (22.2; 44.4) 48 (6.3; 14.6) 28 (3.6; 0) 108 (1.9; 4.6)
  >65 years 30 (80.0, 86.7) 41 (7.3; 2.4) 36 (2.8; 16.7) 12 (16.7; 8.3) 92 (2.2; 3.3)
Primary condition      
 Hematological malignancy 10 (60.0; 80.0) 3 (33.3; 33.3) 6 (33.3; 33.3) 1 (0; 0) 0
  Leukemia 5 (40.0; 80.0) 1 (0; 0) 3 (33.3; 33.3)   
  Lymphoma 3 (100.0; 66.7) 1 (100.0; 100.0) 2 (50.0; 50.0)   
  Myelodysplasia 1 (0; 100.0) 1 (0; 0) 1 (0; 0)   
  Multiple myeloma 1 (100.0; 100.0) 0 (0; 0) 0 (0; 0) 1 (0; 0)  
 Solid tumor 11 (45.5; 81.8) 7 (14.3; 28.6) 10 (0; 30.0) 0 0
  Bronchopulmonary neoplasm 2 (50.0; 50.0) 1 (0; 0) 4 (0; 50.0)   
  Pancreas/colon adenocarcinoma 7 (71.4; 85.7) 6 (16.7; 33.3) 5 (0; 20)   
  Bladder neoplasm 2 (50.0; 100.0) 0 (0; 0) 1 (0; 0)   
 Nonmalignant diseases 80 (77.5; 88.8) 40 (7.5; 5.0) 68 (2.9; 11.8) 39 (7.7; 2.6) 0
  Respiratory dysfunctionb 5 (80.0; 60.0) 18 (11.1; 5.6) 3 (33.3; 33.3) 21 (4.8; 4.8)  
  Gastrointestinal pathologyc 65 (75.4; 92.3) 4 (25.0; 25.0) 60 (1.7; 11.7) 2 (100.0; 0)  
  Othersd 10 (90.0; 80.0) 18 (0; 0) 5 (0; 0) 16 (0; 0)  
Risk factors      
 Iatrogenic predisposing factors      
  Broad spectrum antibiotics 68 (76.5; 86.8)h 44 (4.5; 2.3) 64 (4.7; 9.4) 20 (5.0; 5.0) 0
  Glucocorticoids therapy 57 (87.7; 91.2) 40 (2.5; 2.5) 46 (2.2; 2.2) 0 (0; 0) 0
  Central venous catheters 36 (72.2; 88.9) 28 (0; 0) 27 (0; 0) 9 (0; 0) 0
  Parenteral nutrition 56 (82.1; 92.9) 15 (0; 0) 49 (0; 0) 3 (66.7; 0) 0
Other risk factors      
  Intensive care unit stay 26 (80.8; 92.3)i 12 (8.3; 16.7) 18 (5.6; 11.1) 12 (16.7; 0) 0
 Neutropeniae 11 (36.4; 45.5) 2 (0; 50.0) 3 (0; 33.3) 0 (0; 0) 0
 Acute renal failure 2 (50.0; 50.0) 2 (50.0; 0) 1 (100.0; 0) 0 (0; 0) 0
Outcome of hospital stay      
  Death 36 (63.9; 88.9)j 8 (37.5; 50.0) 10 (20.0; 50.0) 12 (8.3; 8.3)1,1 nk
  Discharge 65 (76.9; 86.2) 42 (4.8; 2.4) 74 (2.7; 10.8) 28 (7.1; 0) nk
  1. a Patients with proven and probable IA.
  2. bIncludes the following diseases: pneumonia, chronic obstructive pulmonary disease, and acute respiratory distress syndrome.
  3. c Includes the following diseases: cholecystitis, angiocholitis, pancreatitis, peritonitis, and hepatitis.
  4. d Includes the following diseases: multiple trauma, acute renal insufficiency, and diabetes mellitus.
  5. e Neutropenia was defined as an absolute neutrophil count below 500 cells/mm3.
  6. f,g,h,I,j No significant difference was found in patients with candidemia associated with age, sex, predisposing factors for IC and clinical outcomes (P > 0.05).
  7. k Not applicable.